Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
MMs set a new record, 99.7 Percent Short Today
That is correct, 13.646 million shares Shorted on a day with 13.679 million shares Total Volume
Date ... Symbol .. Short vol ... Total vol
20230515 | BIEL | 13646000 | 13679625
KW does not have 'first rights to assets', handed over to EXIM Bank years ago
<<<<<<<<<<<<< Kelly walks with the patents >>>>>>>>>>>>>>
Sounds like a moving Goalpost
Post title that I responded was, "Here's a link between Koneru and BIEL", no specific mention of just Clinical Trials.
Dr Koneru is listed as an Author on the Cervical Osteoarthritis Trial as my first post showed
Pulsed Shortwave Therapy in Cervical Osteoarthritis: An NSAID- Controlled, Randomized Clinical Trial
June 2020
DOI:10.21203/rs.3.rs-34236/v1
LicenseCC BY 4.0
Authors:
A. Rachid El Mohammad
new mazloum hospital Tripoli Lebanon
Sree Koneru
BioElectronics Corporation
Richard Staelin
Duke University
Kenneth Mcleod
Binghamton University
Pulsed Shortwave Therapy in Cervical Osteoarthritis: An NSAID- Controlled, Randomized Clinical Trial
June 2020
DOI:10.21203/rs.3.rs-34236/v1
LicenseCC BY 4.0
Authors:
A. Rachid El Mohammad
new mazloum hospital Tripoli Lebanon
Sree Koneru
BioElectronics Corporation
Richard Staelin
Duke University
Kenneth Mcleod
Binghamton University
The absolute reduction from baseline in NDI was significantly greater in the PSWT arm than NSAID arm(by 3.66 points; 95% CI 2.3 to 5.02; p<0.0001). Similarly, the reductions from baseline inVASrest and VASactivitywere significantly greater in the PSWT arm than NSAID arm(by 10.89 mm;95% CI 6.90 to 14.87; p<0.0001 and 12.05 mm;95% CI 7.76 to 16.33; p<0.0001 respectively).The PSWT arm used 50% less rescue pain medication. Eleven adverse effects were reported in the NSAID arm and zero in the PSWT arm. Conclusion Both NSAID and PSWT treatments resulted in clinically meaningful increases in quality of life(NDI) and decreases in pain (VAS) associated with cervicalosteoarthritis. However, the PSWT arm showed superior improvements in all outcome measures when compared to the NSAID arm with no adverse effects.
*******************************************************************
Chronic pain intervention using pulsed shortwave therapy: the relationship between pain demographics and central sensitization inventory
May 2019Pain Management 9(5)
DOI:10.2217/pmt-2018-0032
Authors:
Sree Koneru
BioElectronics Corporation
Richard Staelin
Duke University
Ian M Rawe
The central sensitization inventory (CSI) is a validated, patient-reported questionnaire that quantifies symptoms of hypersensitivity disorders such as chronic pain, for which central sensitization (CS) may be the etiology. Objective: To investigate the analgesic effectiveness of ActiPatch and analyze the relationship between baseline CSI scores and demographics of chronic pain sufferers. Methods: Upon completing a 7-day ActiPatch trial, baseline CSI scores along with other assessment measures were obtained via e-mail from 174 chronic pain sufferers. Conclusion: CSI scores were positively correlated with gender (higher for women), baseline visual analog scale scores and pain duration. ActiPatch was found to be effective in reducing baseline pain for all subjects by an average of 4.3 visual analog scale points.
***************************************************
A Prospective Six-Month Study of Chronic Pain Sufferers: A Novel OTC Neuromodulation Therapy
Hindawi
September 2019Pain Research and Management 2019(3):1-11
DOI:10.1155/2019/3154194
LicenseCC BY
Authors:
Richard Staelin
Duke University
Sree Koneru
BioElectronics Corporation
Ian M. Rawe
To assess the durability of treatment over various chronic pain conditions of an emerging, nonprescription electromagnetic neuromodulation device that uses pulsed shortwave therapy. Methods: A 6-month prospective study, involving 240 chronic pain sufferers, 94% of whom reported using pain pills and 98% reported using pain therapies prior to entering the study. Their average baseline pain was 8.2 VAS points before treatment; they had a pain duration of 6.5 years, and they were positive responders to pulsed shortwave therapy in an initial 7-day trial. Prospective assessments were obtained at intervals of 3, 4, and 6 months following a retrospective 7-day assessment. Longitudinal analyses were conducted to determine pain relief trends after the initial 7-day device use. Results: Seven days after initial treatment, the average pain was reduced to 2.9, a 65% pain reduction for the study subjects. At the 6-month measurement, the average pain was 3.3, a 60% pain reduction from baseline. Only 17% of the subjects saw their pain level increase although this new level was still lower than baseline pain. Pain relief translated into improved quality of life and reduced medication use for the majority of the subjects. There were no significant adverse side effects reported over the 6 months of use. Conclusion: Ninety-seven percent of the recruited subjects, all of whom had previously reported clinically significant pain relief using the 7-day PSWT device, sustained this relief for 6 months by using the device on an as-needed basis.
************************************************
Rectification of RF Fields in Load Dependent Coupled Systems: Application to Non-Invasive Electroceuticals
January 2016Journal of Biomedical Science and Engineering 09(02):112-121
DOI:10.4236/jbise.2016.92007
LicenseCC BY 4.0
Authors:
Sree Koneru
BioElectronics Corporation
Charles R. Westgate
Binghamton University
Kenneth Mcleod
Binghamton University
Electroceuticals are medical devices that employ electric signals to alter the activity of specific nerve fibers to achieve therapeutic effects. The rapid growth of RF microelectronics has resulted in the development of very small, portable, and inexpensive shortwave and microwave radio frequency (RF) amplifiers, raising the possibility of utilizing these new RF technologies to develop non-contact electroceutical devices. However, the bio-electromagnetics literature suggests that beyond 10 MHz, RF fields cannot influence biological tissue, beyond simple heating, because effective demodulation mechanisms at these frequencies do not exist in the body. However, RF amplifiers operating at or near saturation have non-linear interactions with complex loads, and if body tissue creates a complex loading condition, the opportunity exists for the coupled system to produce non-linear effects, that is, the equivalent of demodulation may occur. Correspondingly , exposure of tissue to pulsed RF energy could result in the creation of low frequency de-modulation components capable of influencing tissue activity. Here, we develop a one-dimensional , numerical simulation to investigate the complex loading conditions under which such demodulation could arise. Applying these results in a physical prototype device, we show that up to7.5% demodulation can be obtained for a 40 MHz RF field pulsed at 1 KHz. Implications for this research include the possibility of developing wearable, electromagnetic electroceutical devices .
But What About .....
The Conversion disinformation gets slapped down and now "Interest" is the new Boogie Man.
There is a proper use for the word " IF ", it involves the presence of an unknown
There is no unknown with regards Dr Staelin's loans being convertible. It is spelled out in the Financial Statements, "Conversion Terms - None".
St John's (Patricia Whelan) loans have been the same for the last 2 years, "Conversion Terms - None".
https://www.otcmarkets.com/otcapi/company/financial-report/365548/content
Insiders are using their money to fund company operations, currently a bit more important than buying shares
Richard Staelin, COB
St John's, Patricia Whelan
Erin Sanders, Sales Manager
"4 trades so far today. WHY?", Pretty Simple
People are waiting for an Update from BIEL.
BIEL has been oversold for months as the silence from management and two Quarters of low revenue have created a negative outlook for investors.
IMO, some good news from BIEL and things turnaround rapidly.
Our COB Loaned BIEL Over $450k in 2022
Do you think he might have more info than we do about BIEL's prospects?
C'mon, None of Staelin's many loans have been convertible since he returned to the COB job in 2020
<<<< If he is getting the same 50% discounted priced stock upon conversion >>>>
Amount ....... Maturity .. Conversion ..... Noteholder
$50,000 ....... 01/3/2024 .... None .......... Richard Staelin Revocable Trust
$30,000 ....... 6/24/2024 .... None .......... Richard Staelin Revocable Trust
$100,000 ..... 7/15/2024 .... None ........... Richard Staelin Revocable Trust
$65,000 ...... 10/13/2024 ... None .......... Richard Staelin Revocable Trust
$45,000 ..... 11/16/2024 ... None ........... Richard Staelin Revocable Trust
$55,000 ..... 12/01/2024 ... None ........... Richard Staelin Revocable Trust
$18,000 ..... 12/15/2024 ... None ........... Richard Staelin Revocable Trust
$45,000 ..... 12/23/2024 ... None ........... Richard Staelin Revocable Trust
$40,000 ..... 12/28/2024 ... None ........... Richard Staelin Revocable Trust
It's no secret, displayed prominently in the Financials.
Adcock Ingram, Patience is Rewarded
Adcock Ingram first showed up on the BIEL radar in a November 2020 Chairman Letter.
"Two other firms have also placed orders to sell our device in the domestic OTC market. However, they have yet to distribute their products into retail and thus we are not able to identify them. With this noted, both will be receiving delivery of units in December and thus we anticipate booking sales to these customers in fourth quarter 2020. (These two customers anticipate selling into their retail markets in first quarter 2021.) Internationally, we landed a contract with Adcock, a large firm in South Africa. Adcock is now in the process of registering the product and first sales to them should occur in early 2021."
It took 2 and a half years for Adcock to fully engage in ActiPatch promotions but we now have South African TV commercials touting the advantages of ActiPatch.
There was a once in one hundred years, worldwide pandemic during this period but nobody likes excuses, right.
The next time complaints are voiced about how long Synergy or SAI have been in a holding pattern remember the Adcock Ingram story.
LOL, 34k shares in first hour of trading, such massive "DUMPING"
The BIEL Comedy Show is bringing down the house today.
KT Tape is an OEM Partner, the Wave is KT's product to market as they see fit
BIEL gets paid when they deliver each shipment of the Wave and that is their job in the Partnership.
**************************
The Boots relationship brought BIEL its largest revenues and its largest Net Losses.
Paying the shelf space fees in the UK for 2,000 stores was too expensive compared to the revenue from Boots sales. This fact was an important issue when BIEL chose to stop retail store sales when ActiPatch was added to the NHS Drug Tariff.
You could blame BIEL for not correctly calculating that sales costs would out strip sales revenue but there are many risks all businesses take when entering new markets.
***************************
The national NHS Approval for the Drug Tariff did not include the local NHS approval to use ActipPatch in each of hundreds of community controlled NHS jurisdictions.
This one is a lack of DD by BIEL in not finding out that the Community NHS groups have to approve drugs and devices before their doctors can prescribe them.
The cash strapped Local NHS took a page from US health insurers and declared that there was not enough evidence to approve ActiPatch, more , larger studies were needed.
The recognition of an addition to the NHS Drug Tariff is by itself a valuable asset to BIEL among medical professionals.
********************************
CVS was a 3 way partnership with Protex, the maker of the knee sleeve, having the connections to initiate a limited store trial with ActiPatch at CVS.
The trial had good results and CVS wanted to move forward with more stores but AW felt that BIEL had too small of a percentage in the 3 way relationship.
So you can blame AW for refusing a low margin deal but if he was correct in BIEL not making enough money in a rollout to thousands of CVS stores can you still blame him for taking the Boots deal where revenue did not cover the costs?
*********************************
SAI was never officially acknowledged as a BIEL Partner. SAI said they were going to launch
10 'Powered By ActiPatch' products in the US several years ago but it did not happen, Covid did happen and changed many business expansion plans.
SAI did do an online launch of several 'Powered By ActiPatch' products in Canada through their Canadian branch, Airway.
IMO, we may still see a US launch now that Covid is under control.
***********************************
The Synergy deal has definitely not kept the original estimated time table and I would agree that the lack of an official BIEL Update 8 months after the Conference Call is not good.
Synergy was featured in a PR in March, KitoTech, a wound closure device company, signed a deal with them for 25 countries similar to the BIEL 8/25/2022 CC announcement.
***********************************
KT is a private company, there is no "stock price"
<<<<<<<<< the company has to drop the stock price to sell >>>>>>>>>>
My post mentioned the price of the KT Wave product being too high for 250 hours therapy.
If the drop to $22/$25 increases sales that will help BIEL as KT will need to reorder sooner.
BIEL makes their money when the Wave product is delivered to KT not when KT sells it.
KT needs the Wave as it is the only one of their products with an FDA Clearance.
KT Tape is an athlete/weekend warrior centered brand
This demographic is a small percentage of the overall Pain Relief Market.
KT shot themselves in the foot, as far as attracting current Actipatch users, by pricing the Wave at $34 for 250 hours. It would take $90 of KT Wave purchases to equal one ActiPatch 720 hour purchase at $30. Consumers notice this type of a major price jump and tend to avoid it.
KT has recently dropped the price, currently $22 on Amazon sold by Amazon, $25 on KT's website. This will help but is still far from the ActiPatch cost per hour.
Adcock Ingram supplies pharmacies who help patients relieve all types of pain. Adcock is also using TV promotions for ActiPatch.
"A Lie is A Lie", interesting there was desire to go down that road
<<<<<<< First off there are no Market Makers for this stock. The original MM when the stock went public, which under the rules of that time, were the ONLY people ho could make a market in the stock for 30 days, as reward for filing the 15c2-11. Since then, nearly 19 years there has been NONE. >>>>>>>
"there are no Market Makers for this stock", This Not a True Statement.
All OTC companies have Market Makers. Retail investors don't trade directly with other investors they Sell to MMs and Buy from MMs, this creates market liquidity. This enables a quick execution time for trades. Imagine what would happen to the trading process if each Buy had to be matched with another investor who wanted to Sell the same amount of shares.
When a company wants to trade on the OTC Markets they need a MM to sponsor their entry to the OTC Markets. This involves filing a form with FINRA. The sponsoring MM has a 30 exclusive on handling trades for this new company. After 30 days other MMs can trade the new company with no repeating of the initial FINRA filing.
That's one opinion on the issue
The SEC had been warned for years prior to the Lucia Lawsuit that their hiring and firing power over their Administrative Law Judges was unconstitutional. Judges need to be free from any influence that would sway their decisions, Administrative Law Judges were not
The Judges had pressure placed on them by the SEC to return convictions which resulted in a 90% conviction rate vs similar cases tried by Federal Judges which had a 65% conviction rate.
When the SCOTUS Lucia judgement ruled that hundreds of ALJ trial decisions were invalid due to being decided by unconstitutional Judges the SEC had copious amounts of egg on their face.
The original judgement against BIEL, over $1.6 million, was abandoned for a new amount of $160k. BIEL knew that going through the laborious process of another SEC trial would cost them more in legal fees than the SEC settlement offer of $160k so they agreed.
Great Pic Pro, Adcock Knows How to Promote a New Product
12 Feet Tall Display
Piercing Blue light Reflecting Off Ceiling
Compare to the standard displays on right side of picture
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=171855034
Thanks for the Stats, Shows Interest in BIEL Up this Week
56% Buys this week
44% Sells this week
We have been down this road before and it was a Dead End
The original sponsoring MM for a new stock entering the OTC Markets gets a 30 day exclusive on that Stock. After that 30 days any qualified Market Maker can start Making a Market in that stock.
Market Makers are the middlemen that make a 10 second trade execution possible because you Buy from and Sell to a MM who will sell you shares at the quoted Ask or buy your shares at the quoted Bid. Without the MM as a middleman Trading would be excruciatingly slow as Sellers and Buyers were trying to be matched together.
"A market maker is a trader whose primary job is to create liquidity in the market by buying and selling securities. Market makers are always ready to buy and sell within the market at a publicly-quoted price. Usually, a market maker is a brokerage house, large bank, or other institution. However, it is possible for individuals to be market makers, as well."
"As the name suggests, market makers “create the market.” In other words, they create liquidity in the market by being readily available to buy and sell securities. This creates liquidity within the market. Most importantly, it helps other trades occur smoothly. Without market makers, the market would be relatively illiquid, which would prohibit the ease of trades."
"Here’s how it works: When you sell 5,000 shares of a particular stock, a market maker will purchase it from you at what’s called the bid price. Then, they’ll turn around and sell it to a buyer at the ask price. Market makers can then sell these purchased securities to broker-dealer firms within their exchange. Keep in mind that when market makers purchase securities, they don’t always have a buyer lined up right away."
C'mon, Everyone is aware there were 13 million Buys vs 5 million Sells Today
Calling BS on this failed attempt to spin.
Twice as Many Buys as Sells Today
Buys = 13 million shares
Sells = 5.1 million shares
Neutral = 3.1 million shares (.00045 SP)
OTC Markets sure mentions Market Makers a lot for someone who doesn't use them
A Closer Look at OTC Trading
"Industry-leading market makers, such as Citadel Securities, GTS, Jane Street, StoneX, Susquehanna/G1X and Virtu, make up the diverse community of 90+ regulated broker-dealers providing continuous liquidity and execution services for investors. Market makers attract business by competing on price, execution quality, and their ability to fill large or specialized orders."
"Market makers serve thousands of online, retail, and institutional broker-dealers that send investor orders to be executed electronically, at the best price. With a broad range of industry expertise, our diverse community of regulated market makers can trade everything from smaller, innovative, and entrepreneurial companies, to investor-focused community banks and international companies."
"Making a market is a process whereby a person or brokerage house that is always prepared to buy and sell securities in order to provide liquidity to the markets."
Looking for "Bored Ape Syndrome" I believe
<<<<< What’s that called again? >>>>>
Its not about making money by shaving tiny fractions of a penny off a 100k order
IMO, its about keeping Buy Transactions off the Tape. The drop from 5 to .00045 makes it a Neutral transaction not a Buy, discouraging shareholders, hoping more will Sell. Especially effective on low volume days like yesterday, changing the Tape from 4 Buys totaling 233k and 3 Sells totaling 37k to 1 Buy at 40k , 3 Sells totaling 37k, 3 Neutral totaling 233k.
No Need to worry about the MMs paying the electric bill. Citadel, who handles the lions share of OTC transactions, had profits of $16 billion in 2022.
Nothing to Brag about Today, 3 Sells Totaling 37,000 shares
Buys = 40,000 shares
Sells = 37,000 shares
Neutral = 233,249 shares at .00045
ActiPatch finds another niche market
Now available on the Shot Put Equipment website.
Fun feature, watch the bottom left corner of the ActiPatch page. Recent purchases of ActiPatch with customer name and location pop up every 7- 10 seconds.
https://www.shotputequipmentshop.com/actipatch-advanced-24-hour-pain-relief/
Last time I checked one needs to pass through 5 to get to 6,7,8,9,10,11,12,13,14,15
When BIEL moved from 4 to 5 some may consider it an insignificant one one-hundredth of a cent move.
Those who own BIEL shares and see their BIEL account up by 25% see it differently.
You do realize that Retail Traders can't enter an order for a .00045 price, right?
That means either a retail order, actually 2, one for 150k shares and one for 80k shares, at .0005 were entered and a MM stepped in and sold the shares at .00045 or Broker/Dealers are trading between themselves at 5 digits to the right of the decimal point.
A Trade at .00045 with the Bid at 4 and the Ask at 5 is not a Sell or a Buy.
Which means there has been only one Sell today, 2,000 shares with a value of 80 cents.
Lets see, where have I heard that before .....
Every year for the last 13 years.
Always Wrong.
If you consider 24 hours ago a "VERY long time"
<<<<<< today was the FIRST day in a VERY long time that the buys out weighed the selling >>>>>>
Tuesday, May 02, 2023 5:47:45 PM post # 313264
Ruh Roh, Back to Back 5 million share Buys
Buys = 10.2 million shares
Sells = 8.1 million shares
************************************************************
Wednesday, May 03, 2023 5:04:09 PM post #313315
Your Opinion does not change the Facts:
BIEL Closes at 5 Again Today
More Buys than Sells Again Today
Another Day with a 5 million share Closing Trade
Buys = 17.2 million shares
Sells = 12.8 million shares
Neutral = 12.7 million shares ( .00045 SP)
The last Sell order was at 12:30, 3.5 hours of Trading with zero Sells
Your Opinion does not change the Facts:
BIEL Closes at 5 Again Today
More Buys than Sells Again Today
Another Day with a 5 million share Closing Trade
Buys = 17.2 million shares
Sells = 12.8 million shares
Neutral = 12.7 million shares ( .00045 SP)
That is just an absurd opinion
<<<<<<< Therefore, all dialogue about buy and sell numbers is pointless. >>>>>>>
MMs being able to Short at the Bid and Ask Price has nothing to do with a Trade being classified by its execution price being at the Bid or Ask Price.
<<<<< quoting daily short volume as evidence of manipulation is pointless. >>>>>
The SEC and FINRA do not feel that the Reg SHO Daily Short Report is "pointless". I will go with their opinion.
I responded to yesterday's 5 million $$$ Buy Trade and the claim that it was a "so called 'buy' "
I would be interested to hear why anyone would feel that it was not a Buy of 5 million shares at a price of .0005 , a Buy with the Bid at .0004 and the Ask at .0005.
I don't recall questioning the Q4 or Q1 sales numbers.
Pretty Simple, MMs can sell shares they don't own at both the Ask Price and the Bid Price, either way it is Naked Shorting
<<<<< 12.4 million trades are listed as short sales. That only leaves ~ 6 million for buys >>>>>
If they sell at the Ask Price the transaction is recorded as a Buy.
If they sell at the Bid Price the transaction is recorded as a Sell.
As far as MMs covering their Shorting, do you feel that all transactions between Broker/Dealers are recorded in the daily Time/Sales data that retail investors see?
We have entered 'Alternate Facts' Fantasy Land
<<<<<<<< take away that one so called 'buy' and what do you have? >>>>>>>
When the Bid is at 4 and the Ask is at 5 and a 5 million $$$$ Trade is made at the price of 5 that is a BUY. There is no spinning it as "so called".
Answering the "and what do you have" question, in yesterday's case you have a second 5 million share BUY an hour after the first one with zero Sells in between.
Ruh Roh, Back to Back 5 million share Buys
Buys = 10.2 million shares
Sells = 8.1 million shares
The last Sell order was at 12:30, 3.5 hours of Trading with zero Sells .
Ruh Roh, 5 million share Buy at 5
Buys = 5.2 million shares
Sells = 8.1 million shares
tst
Yep, All Smoke and Mirrors to Project an Illusion
62 Trades to produce $1769 in Dollar Volume.
Averages out to $28.53 per Trade. 'Pitiful Trickle' is the proper description.